Table 2 Box–Behnken experimental design and the observed responses
From: Nanomicelles co-loaded with doxorubicin and salvianolic acid A for breast cancer chemotherapy
Run | Independent variable | Dependent variable | ||||
|---|---|---|---|---|---|---|
X1 | X2 | X3 | Y1 (nm) | Y2 (%)a | Y3 (%)b | |
1 | 0 | 0 | 0 | 17.11 ± 1.30 | 13.3 ± 0.4 | 85.6 ± 4.8 (79.1 ± 3.8, 92.0 ± 4.0) |
2 | 0 | − 1 | − 1 | 18.78 ± 0.75 | 14.5 ± 1.0 | 75.0 ± 2.1 (67.5 ± 2.9, 82.4 ± 2.3) |
3 | 0 | + 1 | + 1 | 17.65 ± 0.97 | 4.5 ± 0.6 | 43.0 ± 2.0 (37.1 ± 1.3, 45.5 ± 5.2) |
4 | 0 | 0 | 0 | 16.99 ± 1.12 | 13.4 ± 1.1 | 92.9 ± 3.3 (87.0 ± 2.5, 98.7 ± 2.8) |
5 | 0 | 0 | 0 | 16.98 ± 0.90 | 13.9 ± 1.5 | 100.4 ± 4.2 (97.1 ± 5.3, 103.6 ± 1.8) |
6 | 0 | − 1 | + 1 | 17.66 ± 2.11 | 8.0 ± 0.7 | 80.6 ± 5.2 (74.9 ± 4.3, 90.4 ± 7.1) |
7 | 0 | 0 | 0 | 16.82 ± 2.01 | 15.1 ± 1.0 | 101.6 ± 15.0 (101.2 ± 12.2, 102.3 ± 12.6) |
8 | + 1 | + 1 | 0 | 17.16 ± 1.01 | 16.5 ± 1.2 | 101.8 ± 2.8 (99.9 ± 3.3, 103.8 ± 1.4) |
9 | − 1 | − 1 | 0 | 224.5 ± 22.34 | 11.7 ± 0.7 | 87.8 ± 4.6 (81.6 ± 3.2, 93.9 ± 4.2) |
10 | − 1 | 0 | + 1 | 15.03 ± 1.67 | 9.9 ± 0.6 | 78.9 ± 6.7 (72.5 ± 5.1, 85.3 ± 5.9) |
11 | 0 | + 1 | − 1 | 16.77 ± 0.52 | 19.8 ± 1.5 | 96.1 ± 8.7 (89.7 ± 7.1, 102.5 ± 7.0) |
12 | + 1 | 0 | − 1 | 18.44 ± 0.73 | 16.6 ± 1.7 | 87.7 ± 5.3 (81.1 ± 4.5, 94.2 ± 4.1) |
13 | + 1 | − 1 | 0 | 266.9 ± 24.21 | 11.7 ± 0.7 | 72.7 ± 6.5 (66.6 ± 5.7, 78.9 ± 4.9) |
14 | + 1 | 0 | + 1 | 18.23 ± 1.31 | 10.6 ± 0.5 | 93.9 ± 8.0 (87.5 ± 6.2, 100.2 ± 6.1) |
15 | 0 | 0 | 0 | 17.46 ± 0.63 | 15.7 ± 1.2 | 91.6 ± 11.3 (85.2 ± 9.2, 98.1 ± 9.3) |
16 | − 1 | + 1 | 0 | 16.06 ± 0.37 | 15.0 ± 1.4 | 84.9 ± 7.8 (78.8 ± 6.0, 90.9 ± 6.8) |
17 | − 1 | 0 | − 1 | 115.5 ± 9.78 | 14.6 ± 0.9 | 61.7 ± 9.1 (55.9 ± 7.8, 67.5 ± 7.1) |